Tag
Saroglitazar significantly improves liver fat content, liver enzymes, and lipid profiles in women with PCOS and MASLD, highlighting its potential as a therapeutic option in this underrepresented population.
Poor food access correlates with higher MASLD and frailty prevalence in liver transplant candidates, with geospatial clustering highlighting socioeconomic and environmental determinants impacting transplant candidacy and outcomes.
Genetic susceptibility to metabolic dysfunction-associated steatotic liver disease (MASLD) is amplified by gut microbiota interactions, with ceramides playing a key role; targeted microbial interventions can reverse hepatic injury in at-ris
A large Korean cohort study found similar hepatic benefits between empagliflozin and dapagliflozin in patients with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease, with no difference in risk of severe liver com
This UK cohort study reveals that both maternal and paternal obesity before pregnancy significantly increase offspring’s risk of metabolic dysfunction associated steatotic liver disease (MASLD) by age 24, largely mediated by excess ch
An international Delphi panel concludes metabolic dysfunction‑associated steatotic liver disease (MASLD) raises colorectal cancer (CRC) risk. Experts call for earlier, risk‑adapted CRC screening and integrated metabolic care to reduce CRC b
This prospective cohort study compares semaglutide, bariatric surgery, and lifestyle therapy in obese patients with MASLD, demonstrating semaglutide and surgery improve liver steatosis and fibrosis markers better than lifestyle changes alon
This study reveals that weight gain exceeding 5% in MASLD patients increases liver-related event risks and liver stiffness, whereas weight loss improves liver stiffness and may reduce adverse outcomes, especially with obesity reversal.
Shear wave elastography (SWE) shows comparable accuracy to vibration-controlled transient elastography (VCTE) for stratifying liver-related event risk in MASLD patients using FIB-4-based two-step algorithms.
This article reviews evidence linking cardiovascular-kidney-metabolic syndrome stages to liver fibrosis severity, progression, and liver-related events in metabolic dysfunction-associated steatotic liver disease (MASLD). Higher CKM stages i
A large-scale proteomic study identified distinct MASLD subtypes influenced by sex differences and developed a four-protein score predicting all-cause mortality, advancing personalized risk assessment beyond traditional liver-centric models
New obesity definitions reclassify many MASLD patients as obese but do not improve prediction of liver-related events over BMI alone, according to a multinational cohort study.
A liver fibrosis risk score (pFIB-6) identifies children with obesity at markedly increased short-term risk of type 2 diabetes, offering a potential tool for early risk stratification.
Older adults with MASLD, especially those aged 75 and above, experience a high burden of polypharmacy linked to multimorbidity, necessitating careful medication management to balance disease control and geriatric vulnerabilities.
The G-MASLD study evaluated the diagnostic accuracy of non-invasive fibrosis tests across 41 countries, revealing regional variability and identifying Agile-3+ and Agile-4 as the most accurate for advanced fibrosis and cirrhosis in MASLD pa
A multicenter study reclassifies pediatric NAFLD under the steatotic liver disease framework, revealing most children meet MASLD criteria, while highlighting alcohol and medication-related reclassifications that inform diagnosis and managem
This study elucidates how KLF9 mediates intermittent hypoxia-induced MASLD by suppressing NR4A1 and p38 MAPK signaling, paving the way for targeted therapies in OSA-associated metabolic liver disease.
The Global-MASLD study identifies key predictors of advanced fibrosis and mortality in metabolic dysfunction-associated steatotic liver disease, highlighting the prognostic value of noninvasive fibrosis markers across diverse populations.
This article explores a novel AI framework that identifies distinct collagen deposition patterns in MASLD, offering improved molecular specificity and prognostic value beyond traditional fibrosis assessments.
In adults with suspected MASH, 200 IU/day vitamin E lowered ALT as effectively as 400 IU/day and 800 IU/day over 24 weeks, with no short-term safety signal, supporting lower-dose use if vitamin E is chosen.
